Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B Well 1
2021-005139-22Phase 3Active
- Sponsor
- GSK
- Start
- Oct 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Bepirovirsen plus nucleos(t)ide analogue with Placebo plus nucleos(t)ide analogue (2 arms). Primary endpoint: Functional cure in participants with baseline HBsAg <1000 IU/mL. Started Oct 2022; status: active.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-005139-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005139-22.